Women's Health has published an explainer on retatrutide, the Eli Lilly drug in phase 3 trials that is being described as the most powerful weight-loss medication in the GLP-1 class so far. Two doctors interviewed for the piece say it is not FDA approved, and that it is already turning up on the gray market anyway.

The existing drugs are the reference points here. Semaglutide (sold as Ozempic and Wegovy) mimics the GLP-1 hormone, which triggers insulin secretion and signals fullness to the brain. Tirzepatide (Mounjaro and Zepbound) adds a second target, GIP. Retatrutide adds a third, glucagon.

The triple G agonist

Holly Lofton, MD, director of the medical weight management program at NYU Langone Health and a principal investigator on a retatrutide trial there, calls it "the triple G agonist." She told Women's Health the added glucagon agonism produces greater delay in gastric emptying and improved fat-cell metabolism, which is the mechanistic reason it acts faster than its predecessors.

The extra receptor does not do everything. Jennifer Manne-Goehler, MD, of Harvard Medical School and a technical consultant on GLP-1s to the World Health Organization, says retatrutide appears to lower glucose in type 2 diabetes about as well as other GLP-1 medications. Weight loss is where it separates.

The number everyone will quote

Lofton compares the magnitude to bariatric surgery: roughly 28 percent of body weight over two years, against about 10 percent with GLP-1s. That is the figure that will drive the headlines, and it is also why she stresses the drug is not for cosmetic weight loss but for clinical obesity, a chronic medical condition.

What the gray market sells

Both doctors warn against unregulated versions, and Lofton's reason is blunter than the usual safety boilerplate: she says she has had reports of patients taking gray-market reta with no weight loss at all, because the compounds often contain no active ingredient, and may contain additives that could be harmful. No quality control, no consistent formulation, no accountability.

What doctors are watching

Gastrointestinal symptoms were the most common adverse events in leading trials, as with other GLP-1s, Manne-Goehler says. Lofton flags three things she is tracking specifically: whether the lost weight includes muscle or bone density, gallbladder health given that rapid weight loss raises gallstone risk on its own, and a heart rate increase seen in phase 2 that was minor, peaked around 24 weeks and resolved. Dysesthesia, or altered skin sensation, has also appeared in early trials and she wants longer follow-up on it.

Bottom line

Phase 3 compares retatrutide with semaglutide and tirzepatide and is the last step before an FDA submission. Lofton's summary is that no completely unexpected safety signal has appeared so far, which is reassuring and also not the same thing as a long-term record.